1-ethylcyclopentanecarboxamide | 17206-20-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 1-ethylcyclopentanecarboxamide
• 英文别名: 1-ethylcyclopentane-1-carboxamide
• CAS: 17206-20-1
• 化学式: C₈H₁₅NO
• 分子量: 141.213
• InChiKey: GQUAFJZXAGFQLR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  43.1
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• [EN] NOVEL CARBOXAMIDE DERIVATIVES AS HIV INHIBITORS<br/>[FR] NOUVEAUX DÉRIVÉS CARBOXAMIDES COMME INHIBITEURS DU VIH
  申请人：HETERO RESEARCH FOUNDATION

  公开号：WO2011061590A1

  公开（公告）日：2011-05-26

  The present invention relates to carboxamide derivatives of Formula (I), where B1, B2, X, L, n, R, R1, R2, Z1, Z2, Rx and Ry are as defined in the claims, as compounds and compositions for inhibiting Human Immunodeficiency Virus (HIV) and process for making the compounds.

  本发明涉及公式（I）的羧酰胺衍生物，其中B1、B2、X、L、n、R、R1、R2、Z1、Z2、Rx和Ry如权利要求中所定义的那样，作为抑制人类免疫缺陷病毒（HIV）的化合物和组合物，以及制备这些化合物的方法。
• QUINAZOLINE DERIVATIVES
  申请人：Eggenweiler Hans Michael

  公开号：US20120238582A1

  公开（公告）日：2012-09-20

  Novel quinazolinamide derivatives of the formula (I), in which R 1 -R 4 and X have the meanings indicated in Claim 1 , are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.

  式（I）中的新型喹唑啉酰胺衍生物，其中R1-R4和X具有权利要求书中指示的含义，是HSP90抑制剂，可用于制备用于治疗HSP90起作用的疾病的药物。
• COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE
  申请人：SHY Therapeutics LLC

  公开号：US20170174699A1

  公开（公告）日：2017-06-22

  Provided herein are compounds that inhibit the phosphorylation of MAPK and thus are useful in compositions and methods for treating cancer and inflammatory disease.

  本文提供了抑制MAPK磷酸化的化合物，因此可用于治疗癌症和炎症性疾病的组合物和方法。
• 4-PHENYL-1,3-THIAZOLES AND 4-PHENYL-1,3-OXAZOLES DERIVATIVES AS CANNABINOID RECEPTOR LIGANDS
  申请人：Harnett Jeremiah

  公开号：US20110059970A1

  公开（公告）日：2011-03-10

  The present invention relates to new 4-phenyl-1,3-azole derivatives having the general formula (I) wherein R1, R2, R3, R4, X, A, B, and n are variable, in a racemic form, an enantiomeric form or any combinations thereof. These compounds exhibit affinity for cannabinoid receptors and may therefore be used as drugs to treat or prevent pathological states and diseases in which one or more of these receptors are involved. The invention also relates to pharmaceutical compositions containing said products and to the use thereof to prepare a drug.

  本发明涉及具有一般式(I)的新4-苯基-1,3-唑衍生物，其中R1、R2、R3、R4、X、A、B和n是可变的，在消旋形式、对映异构体形式或任何组合中。这些化合物对大麻素受体具有亲和力，因此可用作药物治疗或预防涉及其中一个或多个这些受体的病理状态和疾病。本发明还涉及含有所述产品的药物组合物以及利用它们制备药物的用途。
• 4-AMINO-5-OXO-7,8-DIHYDROPYRIMIDO[5,4-F][1,4]OXAZEPIN-6(5H)-YL PHENYL DERIVATIVES
  申请人：Aspnes Gary E.

  公开号：US20100204119A1

  公开（公告）日：2010-08-12

  The invention provides compounds of Formula (I), wherein R 1 , R 2a , R 2b , R 3 , m and A are as defined herein, as well as compositions thereof and methods for treating a disease, condition or disorder that is modulated by the inhibition of the diacylglycerol O-acyltransferase 1 (DGAT-1) enzyme by administering the compounds of the present invention and/or compositions thereof.

  本发明提供了式（I）的化合物，其中R1，R2a，R2b，R3，m和A如本文所定义，以及它们的组合物和通过给予本发明的化合物和/或组合物来抑制二酰甘油O-酰基转移酶1（DGAT-1）酶而治疗受DGAT-1调节的疾病，情况或紊乱的方法。